S. Russo

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

M. Fellhauer, A. Hochhaus, I. Gehrke, 2020, Leukemia.

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study

R. Foà, R. Latagliata, G. Saglio, 2023, Frontiers in Pharmacology.

Temozolomide (TMZ) in radio-chemotherapy combined schedule for treatment of newly-diagnosed high-grade gliomas (HGG)

S. Rizzo, I. Carreca, P. Guerrieri, 2005 .

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial

K. Döhner, K. Träger, D. Drömann, 2023, Leukemia.